Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30

The Society for Neuro-Oncology (SNO) marks its 30th anniversary in 2025, providing an opportunity to reflect on scientific advances and future directions in the field. Over 3 decades, SNO has catalyzed scientific innovation, education, mentorship, and global collaboration, advancing the care of patients with primary and metastatic brain tumors. Through its annual meeting and subspecialty conferences in pediatric neuro-oncology and brain metastases, as well as its journals, including Neuro-Oncology, Neuro-Oncology Practice, Neuro-Oncology Advances, and the recently launched Neuro-Oncology Pediatrics, SNO has established leading platforms for disseminating knowledge, sharing best practices, and shaping clinical, translational, and basic research worldwide. Scientific milestones during this period include the integration of molecular profiling into central nervous system tumor classification, advances in neuroimaging for diagnosis and treatment monitoring, targeted therapies for selected glioma patients, and the evolution of brain metastases management from whole-brain radiotherapy to multimodal strategies that incorporate targeted and immune-based therapies. Pediatric neuro-oncology has similarly advanced with the use of histomolecular diagnostics, refined risk stratification, and the development of novel targeted agents, alongside an increased emphasis on survivorship. Looking forward, emerging insights into the tumor microenvironment and novel immunotherapeutic approaches offer promising directions for future discovery and translation.